In this episode, John Gagliano and Sheff Sheffield discuss the current state of the biotech market as they approach the end of the year. They reflect on recent trading successes and challenges, emphasizing the importance of understanding catalysts and market reactions. The conversation also highlights the significance of insider trading and institutional movements in stock performance. Finally, they explore upcoming catalysts and provide insights into their stock watchlist for the remainder o...
All content for Biotech Bulls & Breakthroughs is the property of BioPharmCatalyst and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode, John Gagliano and Sheff Sheffield discuss the current state of the biotech market as they approach the end of the year. They reflect on recent trading successes and challenges, emphasizing the importance of understanding catalysts and market reactions. The conversation also highlights the significance of insider trading and institutional movements in stock performance. Finally, they explore upcoming catalysts and provide insights into their stock watchlist for the remainder o...
Ep. 3: Stock Picking and Catalyst Research | Biotech Bulls & Breakthroughs Podcast
Biotech Bulls & Breakthroughs
1 hour 1 minute
4 months ago
Ep. 3: Stock Picking and Catalyst Research | Biotech Bulls & Breakthroughs Podcast
In this episode, John Gagliano and Sheff discuss current trends in the biotech market, focusing on investment strategies, the importance of catalyst dates, and stock evaluation. Sheff shares insights on his watchlist for upcoming biotech plays, emphasizing the importance of due diligence in making informed investment decisions. The conversation highlights the potential of small-cap stocks and the dynamics of trading around specific actionable dates. In this episode: 🔹Investors should conside...
Biotech Bulls & Breakthroughs
In this episode, John Gagliano and Sheff Sheffield discuss the current state of the biotech market as they approach the end of the year. They reflect on recent trading successes and challenges, emphasizing the importance of understanding catalysts and market reactions. The conversation also highlights the significance of insider trading and institutional movements in stock performance. Finally, they explore upcoming catalysts and provide insights into their stock watchlist for the remainder o...
